- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03132506
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research Focused on Capture of Patient Reported Outcomes With Within PRAEGNANT Study Network
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Paperbacked pPRO data from up to a total of 100 patients from the cohort of PRAEGNANT are planned to be included in the Pepper I PRO study. Additionally 200 patients will be recruited in the web based ePRO cohort. The study duration per patient is at least 8 weeks. In cases of stable disease the study duration can be extended to up to 6 months with monthly PRO assessments, according to the attached visit matrix, taking approximately 20 minutes per visit.
The documentation at baseline should be performed during clinical routine with trained study personnel followed by remote self-reporting to minimize the patient effort. Pepper I will be conducted as sub-protocol of the PRAEGNANT trial.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiekontakt
- Navn: Markus Wallwiener, MD
- Telefonnummer: 0049 6221 56-36956
- E-mail: markus.wallwiener@med.uni-heidelberg.de
Studiesteder
-
-
-
Tübingen, Tyskland, 72076
- Rekruttering
- Department for Women's Health
-
Kontakt:
- Andreas Hartkopf, Prof. Dr.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients enrolled in PRAEGNANT
- Women aged ≥18 years
- Patients with the diagnosis metastasized breast cancer undergoing any form of systemic therapy
- Patients who are willing and able to sign the informed consent form
- Patients with therapy change
Exclusion Criteria:
- Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician
- Patients who are not able to handle a tablet computer or are unable to write
- Patients who are not able to understand the nature and extent of the trial and the procedures require
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Andet
- Tidsperspektiver: Fremadrettet
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
paper-based patient-reported-outcomes
|
Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
|
on web-based patient-reported-outcomes
|
Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
QLQ-C30 questionnaire for baseline
Tidsramme: 8 weeks
|
Overall patient completion rate in the paperbacked questionnaire and the web-tool, respectively
|
8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
All other questionnaires for baseline and follow up time points.
Tidsramme: Baseline, 8 weeks
|
Overall patient completion rate in the paperbacked questionnaire and the web-tool, respectively,
|
Baseline, 8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
age
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
line of treatment
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
treatment
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
technical skills
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
patient's satisfaction
|
8 weeks
|
Adverse events-1
Tidsramme: 8 weeks
|
The date of clinical diagnosis of AE compared with the date of early AE onset
|
8 weeks
|
Adverse events-2
Tidsramme: 8 weeks
|
Consistency of AE documentation ePRO and clinician based
|
8 weeks
|
Patient satisfaction
Tidsramme: baseline, 4 weeks, 8 weeks
|
at baseline, after 4 weeks and after 8 weeks
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
EORTC QLQ C-30
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
BR23
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
NCCN distress thermometer,
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
EQ-VAS
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
PHQ-9
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -2
Tidsramme: baseline, 8 weeks
|
The HRQL assessements EQ-5D-5L measured at baseline and weekly (8 weeks)
|
baseline, 8 weeks
|
Health related quality of life (HRQL) assessements -2
Tidsramme: baseline, 8 weeks
|
The HRQL assessements PROCTCAE Endocrine measured at baseline and weekly (8 weeks)
|
baseline, 8 weeks
|
Health related quality of life (HRQL) assessements -2
Tidsramme: baseline, 8 weeks
|
The HRQL assessements PROCTCAE taxane measured at baseline and weekly (8 weeks)
|
baseline, 8 weeks
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- PEPPER
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft Metastatisk
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien
Kliniske forsøg med patient-reported-outcomes
-
Centre Hospitalier Universitaire de NīmesAfsluttet
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRekrutteringBrystkræft | Kolorektal cancerCanada
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)Ikke rekrutterer endnu
-
University of California, San FranciscoIkke rekrutterer endnuGastrointestinale kræft | Gastrointestinal cancer metastatiskForenede Stater
-
University of Michigan Rogel Cancer CenterAstraZenecaAfsluttetFarmaceuter Coordinated Care Oncology Model (PCOM) for patienter, der tager oral anti-cancer medicinKronisk lymfatisk leukæmi | Kronisk myeloid leukæmi | Flere kroniske tilstandeForenede Stater
-
Medizinische Hochschule Brandenburg Theodor FontaneUniversity of JenaRekruttering
-
University Hospital, Basel, SwitzerlandAfsluttetSkade af det forreste korsbånd (ACL)Schweiz
-
University of Colorado, DenverNational Cancer Institute (NCI)RekrutteringBørnekræft | OverlevelseForenede Stater
-
Taipei Veterans General Hospital, TaiwanRekrutteringSystemisk lupus erythematosus | Tørre øjne syndrom | Sjögrens syndromTaiwan